alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 2700.765 How may I appeal my suspension? ( a ) If the SBA suspending official issues a decision under § 180.755 to continue your suspension after you present information in opposition to that suspension under § 180.720, you may ask for review of the suspending official's decision in two ways: ( 1 ) You may ask the suspending official to reconsider the decision for material errors of fact or law that you believe will change the outcome of the matter; or
( 2 ) You may request that the SBA Office of Hearings and Appeals (OHA) review the suspending official's decision to continue your suspension within 30 days of your receipt of the suspending official's decision under § 180.755 or paragraph (a)(1) of this section. However, OHA may reverse the suspending official's decision only where OHA finds that the decision is based on a clear error of material fact or law, or where OHA finds that the suspending official's decision was arbitrary, capricious, or an abuse of discretion. You may appeal the suspending official's decision without requesting reconsideration, or you may appeal the decision of the suspending official on reconsideration. The procedures governing OHA appeals are set forth in 13 CFR part 134.
( b ) A request for review under this section must be in writing; state the specific findings you believe to be in error; and include the reasons or legal bases for your position.
( c ) OHA, in its discretion, may stay the suspension pending review of the suspending official's decision.
( d ) The SBA suspending official and OHA must notify you of their decision under this section, in writing, using the notice procedures set forth at §§ 180.615 and 180.975.
Editorial Note on Part 112
Editorial Note: Nomenclature changes to part 112 appear at 81 FR 49896, July 29, 2016.

§ 112.181 What procedures apply if FDA determines that an approved variance should be modified or revoked? ( a ) We will provide the following notifications: ( 1 ) We will notify a State, tribe, or a foreign country directly, in writing at the address identified in its petition, if we determine that a variance granted in response to its petition should be modified or revoked. Our direct, written notification will provide the State, tribe, or foreign country with an opportunity to request an informal hearing under part 16 of this chapter.
( 2 ) We will publish a notice of our determination that a variance should be modified or revoked in the Federal Register. This notice will establish a public docket so that interested parties may submit written comments on our determination.
( 3 ) When applicable, we will: ( i ) Notify in writing any States, tribes, or foreign countries where a variance applies to similarly situated persons of our determination that the variance should be modified or revoked;
( ii ) Provide those States, tribes, or foreign countries with an opportunity to request an informal hearing under part 16 of this chapter; and
( iii ) Include in the Federal Register notice described in paragraph (a)(2) of this section public notification of our decision to modify or revoke the variance granted to States, tribes, or foreign countries in which similarly situated persons are located.
( b ) We will consider submissions from affected States, tribes, or foreign countries and from other interested parties as follows: ( 1 ) We will consider requests for hearings by affected States, tribes, or foreign countries under part 16 of this chapter. ( i ) If FDA grants a hearing, we will provide the State, tribe, or foreign country with an opportunity to make an oral submission. We will provide notice on our Web site of the hearing, including the time, date, and place of the hearing.
( ii ) If more than one State, tribe, or foreign country requests an informal hearing under part 16 of this chapter about our determination that a particular variance should be modified or revoked, we may consolidate such requests (for example, into a single hearing).
( 2 ) We will consider written submissions submitted to the public docket from interested parties.
( c ) We will provide notice of our final decision as follows: ( 1 ) On the basis of the administrative record, FDA will issue a written decision, as provided for under part 16 of this chapter.
( 2 ) We will publish a notice of our decision in the Federal Register. The effective date of the decision will be the date of publication of the notice.
Court of Appeals

of the State of Georgia

ATLANTA,____________________

The Court of Appeals hereby passes the following order:

A19A1157. WHITESTONE INVESTMENTS, INC. et al. v. PAUL JASON

MANN.

In this breach-of-contract action, Plaintiff Paul Jason Mann filed suit against

Whitestone Investments, Inc. (“Whitestone”), Roger Blankenship d/b/a Whitestone

Investments (“Blankenship”), and Cleanco Cleaning and Restoration a/k/a Cleanco

Property Maintenance, LLC (“Cleanco”). Whitestone and Blankenship moved for

summary judgment against all Plaintiff’s claims, which the trial court granted.

Thereafter, Whitestone and Blankenship filed a motion for attorney fees pursuant to

OCGA § 9-15-14 against the Plaintiff. In an order dated August 24, 2018, the trial

court denied the motion for attorney fees. Whitestone and Blankenship then filed the

instant direct appeal. We, however, lack jurisdiction.

“In a case involving multiple parties or multiple claims, a decision adjudicating

fewer than all the claims or the rights and liabilities of less than all the parties is not

a final judgment.” Johnson v. Hosp. Corp. of America, 192 Ga. App. 628, 629 (385

SE2d 731) (1989) (citation and punctuation omitted). Although the trial court granted

summary judgment to Whitestone and Blankenship in its entirety, the Plaintiff’s

claims against Cleanco have not been adjudicated and remain pending below. “In

such circumstances, there must be an express determination under OCGA § 9-11-54

(b) or there must be compliance with the interlocutory appeal requirements of OCGA

§ 5-6-34 (b). Where neither of these code sections [is] followed, the appeal is

premature and must be dismissed.” Id. (citation and punctuation omitted).

The trial court’s order in this case did not direct the entry of judgment pursuant

to OCGA § 9-11-54 (b). Therefore, the challenged order is not a final order, and it is

January 31, 2019
appealable only through the interlocutory appeal procedures set forth in OCGA §

5-6-34 (b). See id.; Shoenthal v. Shoenthal, 333 Ga. App. 729, 730 (776 SE2d 663)

(2015). Whitestone and Blankenship’s failure to follow the proper appellate

procedure deprives us of jurisdiction to consider this direct appeal, which is hereby

DISMISSED.

1

Court of Appeals of the State of Georgia

Clerk’s Office, Atlanta,____________________

I certify that the above is a true extract from

the minutes of the Court of Appeals of Georgia.

Witness my signature and the seal of said court

hereto affixed the day and year last above written.

, Clerk.

1 Even assuming that the trial court’s order denying Whitestone and

Blankenship’s motion for attorney fees constituted a final order, this direct appeal

would be subject to dismissal because an appeal from a trial court order awarding or

denying OCGA § 9-15-14 attorney fees must be initiated by filing an application for

discretionary review. See OCGA § 5-6-35 (a) (10), (b); Capricorn Systems, Inc. v.

Godavarthy, 253 Ga. App. 840, 841-842 (560 SE2d 730) (2002).

01/31/2019
##### 



Exhibit 31.1
 CERTIFICATION OF PRESIDENT PURSUANT TO SECURITIES ACT
RULES 13A-14 AND 15D-14 AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
  1.
    
    I have reviewed this quarterly report (report) on Form 10-Q of Del Taco Income Properties
IV;
 2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
 3.
    
    Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;
 4.
    
    The registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) for the registrant and have:
 a)
    
    Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which
this report is being prepared;b)
    
    Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; andc)
    
    Disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter
(the registrants fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrants
internal control over financial reporting; and
 5.
    
    The registrants other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the
audit committee of registrants board of directors (or persons performing the equivalent
function):
 a)
    
    All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrants ability to record, process, summarize and report financial
information; andb)
    
    Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal controls over financial
reporting.
 Date: November 14, 2007
    
    /s/ Shirlene LopezShirlene LopezPresident
# L_2009103DE.01003002.xml

| 23.4.2009 | DE | Amtsblatt der Europäischen Union | L 103/30 |
| --- | --- | --- | --- |

23.4.2009

DE

Amtsblatt der Europäischen Union

L 103/30

---

Berichtigung der Richtlinie 94/45/EG des Rates vom 22. September 1994 über die Einsetzung eines Europäischen Betriebsrats oder die Schaffung eines Verfahrens zur Unterrichtung und Anhörung der Arbeitnehmer in gemeinschaftsweit operierenden Unternehmen und Unternehmensgruppen

(
  Amtsblatt der Europäischen Union L 254 vom 30. September 1994
  )

Amtsblatt der Europäischen Union L 254 vom 30. September 1994

Seite 69, Artikel 8 Absatz 1 Unterabsatz 3:

anstatt:

„Diese Verpflichtung besteht unabhängig von ihrem Aufenthaltsort und selbst nach Ablauf ihres Mandats weiter.“

muss es heißen:

„Diese Verpflichtung besteht unabhängig vom Aufenthaltsort der in Unterabsatz 1 und 2 genannten Personen und selbst nach Ablauf ihres Mandats weiter.“

---
# EUR-Lex - 31991D0133 - EN

Avis juridique important

*|*

# 31991D0133

**91/133/EEC: Council Decision of 4 March 1991 amending Decision 90/424/EEC on expenditure in the veterinary field **

*
Official Journal L 066 , 13/03/1991 P. 0018 - 0018 Finnish special edition: Chapter 3 Volume 36 P. 0214 Swedish special edition: Chapter 3 Volume 36 P. 0214 *

COUNCIL DECISION of 4 March 1991 amending Decision 90/424/EEC on expenditure in the veterinary field (91/133/EEC)

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community,

Having regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field (1), and in particular Article 24 (1) thereof,

Having regard to the proposal from the Commission,

Whereas Decision 90/424/EEC provides for the possibility of a financial contribution from the Community for the eradication and monitoring of the diseases contained in the list annexed to that Decision; whereas the list may be supplemented or amended to take account of developments in the health situation in the Community;

Whereas, in the light of these developments, contagious bovine pleuropneumonia should be added to the list in question so that a Community financial contribution can be obtained for the implementation of programmes for the eradication and monitoring of the disease,

HAS ADOPTED THIS DECISION:

Article 1

The following indent shall be added to Group 1 of the Annex to Decision 90/424/EEC:

'- Contagious bovine pleuropneumonia'.

Article 2

This Decision is addressed to the Member States.

Done at Brussels, 4 March 1991.

For the Council

The President

R. STEICHEN

(1) OJ No L 224, 18. 8. 1990, p. 19.
228 So.2d 486

#### Marvin PONTHIEUX v. STATE of Louisiana.

No. 50185.

Dec. 15, 1969.

In re: Marvin Ponthieux applying for writ of habeas corpus.

On the basis of information furnished by the Attorney General disclosing that applicant has been released from custody in the State Penitentiary, the matter is moot.
Editorial Note on Part 112
Editorial Note: Nomenclature changes to part 112 appear at 81 FR 49896, July 29, 2016.

§ 112.147 What must I do to collect and test samples of spent sprout irrigation water or sprouts for pathogens? All of the following requirements apply for collecting and testing samples of spent sprout irrigation water or sprouts for pathogens as required in § 112.144(b): ( a ) You must establish and implement a written sampling plan that identifies the number and location of samples (of spent sprout irrigation water or sprouts) to be collected for each production batch of sprouts to ensure that the collected samples are representative of the production batch when testing for contamination.
( b ) In accordance with the written sampling plan required under paragraph (a) of this section, you must aseptically collect samples of spent sprout irrigation water or sprouts, and test the collected samples for pathogens using a method as set forth in § 112.153. You must not allow the production batch of sprouts to enter into commerce unless the results of the testing of spent sprout irrigation water or sprouts are negative for *E. coli* O157:H7, *Salmonella* species, and, if applicable, a pathogen meeting the criteria in § 112.144(c).
( c ) Your written sampling plan must include a corrective action plan that at a minimum, requires you to take the actions in § 112.148, and details when and how you will accomplish those actions, if the samples of spent sprout irrigation water or sprouts test positive for *E. coli* O157:H7, *Salmonella* species, or a pathogen meeting the criteria in § 112.144(c).
#### § 2424.332 What methods must I use to pass requirements down to participants at lower tiers with whom I intend to do business?

To communicate the requirements to lower-tier participants, you must include a term or condition in the transaction requiring compliance with subpart C of the OMB guidance in 2 CFR part 180, as supplemented by this subpart.
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 89 Introduced in House (IH)]

<DOC>

115th CONGRESS
  1st Session
                                 H. R. 89

To amend subtitle IV of title 40, United States Code, regarding county 
                  additions to the Appalachian region.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 3, 2017

Mrs. Blackburn introduced the following bill; which was referred to the 
             Committee on Transportation and Infrastructure

_______________________________________________________________________

                                 A BILL

 
To amend subtitle IV of title 40, United States Code, regarding county 
                  additions to the Appalachian region.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ADDITIONS TO APPALACHIAN REGION.

    Section 14102(a)(1)(K) of title 40, United States Code, is 
amended--
            (1) by inserting ``Hickman,'' after ``Hawkins,'';
            (2) by inserting ``Perry,'' after ``Overton,''; and
            (3) by inserting ``Wayne,'' after ``Washington,''.
                                 <all>
```
#### § 1230.16 Exemption from labeling directions for treatment.

Manufacturers and wholesalers only, at the time of shipment or delivery for shipment, are exempted from placing directions for treatment on the label or sticker of any container for other than household use, but in any event the information required by section 2(b) (1), (2), and (3) of the act (44 Stat. 1407; 15 U.S.C. 402) and the regulations in this part shall be given.
#### § 1250.90 Toilets and lavatories.

Toilet and lavatory equipment and spaces shall be maintained in a clean condition.
#### § 3369.220 What contracts and subcontracts, in addition to those listed in 2 CFR 180.220, are covered transactions?

Although the OMB guidance at 2 CFR 180.220(c) allows a Federal agency to do so (also see optional lower tier coverage in the figure in the appendix to 2 CFR part 180), NEH does not extend coverage of nonprocurement suspension and debarment requirements beyond first-tier procurement contracts under a covered nonprocurement transaction.
###### Editorial Note on Part 72

#### Editorial Note:

Nomenclature changes to part 72 appear at 80 FR 74981, Dec. 1, 2015, and at 81 FR 86910, Dec. 2, 2016.

#### § 72.7 Specific exemptions.

The Commission may, upon application by any interested person or upon its own initiative, grant such exemptions from the requirements of the regulations in this part as it determines are authorized by law and will not endanger life or property or the common defense and security and are otherwise in the public interest.
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 675 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
H. RES. 675

      Condemning the Government of Iran for its violence against 
 demonstrators and calling for peaceful resolution to the concerns of 
                         the citizens of Iran.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 3, 2018

    Mr. Banks of Indiana (for himself, Mr. Messer, and Mr. Rokita) 
                   submitted the following resolution

                            January 8, 2018

              Referred to the Committee on Foreign Affairs

_______________________________________________________________________

                               RESOLUTION

 
      Condemning the Government of Iran for its violence against 
 demonstrators and calling for peaceful resolution to the concerns of 
                         the citizens of Iran.

Whereas, on December 28, 2017, citizens began protesting the Government of Iran 
        across the country in the cities and towns of Dorud, Khomaini Shahr, 
        Najafabad, Qahdarijan, Tehran, and Tuyserkan;
Whereas so far 20 people have been killed and 450 have been arrested since 
        demonstrations first began;
Whereas the United States is committed to promoting universal human rights, 
        specifically freedom of speech and freedom of assembly;
Whereas the Government of Iran has provided monetary support to terrorist 
        organizations such as Hezbollah and Hamas; and
Whereas the citizens of Iran deserve the support of the international community 
        in their pursuit of a democratic government that respects human rights 
        and freedoms: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) condemns the Government of Iran--
                    (A) for its funding of terrorist organizations and 
                activities;
                    (B) for the continued oppression of its citizens; 
                and
                    (C) for the suppression of communication through 
                interference with internet applications such as 
                Instagram, Facebook, Telegram, and Twitter; and
            (2) reaffirms--
                    (A) the commitment of the United States to 
                preserving and promoting the freedoms of speech and 
                assembly as universal rights; and
                    (B) the support of the United States for the 
                citizens of Iran to establish a freely elected, 
                democratic system.
                                 <all>
```
CLERK OF THE SUPREME COURT ELIZABETH A. BROW BY: IN THE SUPREME COURT OF THE STATE OF NEVADA
MADELINE MORRISON, Appellant, vs. RICHARD ZUCKER; HILLSDALE COLLEGE; FISHER HOUSE FOUNDATION; SOUTHWESTERN LAW SCHOOL; JIM RUZICKA; AND ELAINE STREGER, Res•ondents. No. 83700 

# ILE SEP 2 0 2022 CLERre

tiETH V
•-•' • ( P kE7V R E O A N URT BY DEPUTY CLERK

ORDER DISMISSINGAPPEAL Cause appearing, appellant's motion for a voluntary dismissal ofthis appeal is granted. This appeal is dismissed. NRAP 42(b).

It is so ORDERED.

cc: Hon. Gloria Sturman, District Judge Law Offices of Mitchell S. Sisson Goldsmith & Guymon, P.C. Elaine Streger Jim Ruzicka Lee Kiefer & Park, LLP Michaelson Law Richard Zucker Eighth District Court Clerk



### 0 2.2. -PMLiti SUPREME COURT OF NEVADA CLERK'S ORDER
Exhibit 32.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

In connection with the Quarterly Report of Calgon Carbon Corporation (the
Company) on Form 10-Q for the period ended March 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Leroy M. Ball, Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully
complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and result of operations of the Company for the periods presented therein.



|                                    
|------------------------------------
|                                    
|/s/ Leroy M. Ball                   
|                                    
|                                    
|Chief Financial Officer May 10,
2006

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and
shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.